黄素加上皮佩林可改善炎症性肠病患者的身体组成:一项随机,双盲,安慰剂控制的临床试验
Amylly Sanuelly da Paz Martins1, Orlando Roberto Pimentel de Araújo2, Amanda da Silva Gomes3
1Pós-Graduação da Rede Nordeste de Biotecnologia (RENORBIO), Universidade Federal de Alagoas (UFAL), Maceió, 57072-970, AL, Brazil.
European journal of nutrition
|February 11, 2025
概括
黄素加上皮佩林补充剂改善了炎症性肠病 (IBD) 患者的肌肉质量和身体组成. 这种组合治疗显示出增强IBD患者营养状况的潜力.
科学领域:
- 营养科学 营养科学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD) 与身体组成的显著改变有关,包括肌肉衰竭和肥胖.
- 目前对IBD的治疗策略往往无法完全解决这些代谢并发症.
- 黄素和皮佩林是具有抗炎性能的天然化合物,可能会影响身体成分.
研究的目的:
- 评估口服库尔库明和库尔库明加皮佩林补充剂对轻度至中度IBD患者的身体组成,相位角度和功能能力的影响.
- 为了比较单独的黄素与黄素与 piperine 结合的疗效与安慰剂.
主要方法:
- 一个为期12周的随机对照试验,涉及58名轻度至中度IBD患者.
- 参与者被分配到安慰剂,黄素 (1000毫克/天) 或黄素加Piperine (1000毫克/天+10毫克/天) 组.
- 身体组成 (BMI,体脂百分比,无脂肪质量),相角 (生物电阻分析) 和手握强度在干预前后进行了评估.
主要成果:
- 与安慰剂相比,黄素加皮佩林组显示肌肉消耗显著减少,无脂肪质量 (p=0.049) 和相角 (p=0.028) 显著改善.
- 最初,研究群体中肥胖 (43.1%) 和肌肉衰竭 (86.3%) 的发病率很高.
- 两组之间没有观察到功能能力 (手握强度) 的显著差异.
结论:
- 黄素与皮佩林结合,通过增加轻度至中度IBD患者的肌肉质量,显著改善了身体组成.
- 这种组合疗法作为一种有效的辅助治疗,有望在IBD中管理营养状况.
- 需要进一步的研究来探索黄素和皮佩林在IBD管理中的长期影响和最佳剂量.
更多相关视频
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
304
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
304
Inflammatory Bowel Disease IV: Pharmacological Management
99
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
99
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Inflammatory Bowel Disease II: Crohn's Disease
171
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
171
Inflammatory Bowel Disease I: Ulcerative Colitis
126
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
126
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
94
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
94


